A Twice-Yearly Injection Cut Clotting Factor XI by 92%, With No Major Bleeding
A twice-yearly injection cut clotting Factor XI activity by 92% in coronary artery disease patients, with no major bleeding events in the Phase 2a study.
Anticoagulation